WO2024120471A1 - Composés ciblant un mutant de p53 - Google Patents
Composés ciblant un mutant de p53 Download PDFInfo
- Publication number
- WO2024120471A1 WO2024120471A1 PCT/CN2023/136981 CN2023136981W WO2024120471A1 WO 2024120471 A1 WO2024120471 A1 WO 2024120471A1 CN 2023136981 W CN2023136981 W CN 2023136981W WO 2024120471 A1 WO2024120471 A1 WO 2024120471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membered
- alkyl
- heterocycloalkyl
- cycloalkyl
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 134
- 230000008685 targeting Effects 0.000 title description 8
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- -1 benzimidazolonyl Chemical group 0.000 claims description 747
- 229910052757 nitrogen Inorganic materials 0.000 claims description 146
- 125000001072 heteroaryl group Chemical group 0.000 claims description 75
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 68
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 62
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 61
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 56
- 229910052805 deuterium Inorganic materials 0.000 claims description 55
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 53
- 125000001424 substituent group Chemical group 0.000 claims description 49
- 125000004429 atom Chemical group 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 46
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 44
- 125000000623 heterocyclic group Chemical group 0.000 claims description 43
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 41
- 125000005842 heteroatom Chemical group 0.000 claims description 36
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 35
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 35
- 125000004043 oxo group Chemical group O=* 0.000 claims description 34
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 21
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 102200106583 rs121912666 Human genes 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 125000002619 bicyclic group Chemical group 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 13
- 239000000651 prodrug Substances 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000002950 monocyclic group Chemical group 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000003367 polycyclic group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 108010021466 Mutant Proteins Proteins 0.000 claims description 6
- 102000008300 Mutant Proteins Human genes 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 102200104166 rs11540652 Human genes 0.000 claims description 5
- 102200069225 rs121434640 Human genes 0.000 claims description 5
- 102200104161 rs121912651 Human genes 0.000 claims description 5
- 102200068968 rs200188353 Human genes 0.000 claims description 5
- 102200104847 rs28934574 Human genes 0.000 claims description 5
- 102200106275 rs28934575 Human genes 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 125000002723 alicyclic group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 102200101620 rs104894442 Human genes 0.000 claims description 4
- 102200108481 rs121912654 Human genes 0.000 claims description 4
- 102200016737 rs72552294 Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Chemical group 0.000 claims description 2
- 208000037844 advanced solid tumor Diseases 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 102200059506 rs281875236 Human genes 0.000 claims 2
- 239000012636 effector Substances 0.000 abstract description 3
- 230000005760 tumorsuppression Effects 0.000 abstract description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 307
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 275
- 239000011541 reaction mixture Substances 0.000 description 246
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 215
- 238000006243 chemical reaction Methods 0.000 description 199
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 175
- 239000007787 solid Substances 0.000 description 166
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 147
- 239000012298 atmosphere Substances 0.000 description 126
- 239000000243 solution Substances 0.000 description 117
- 239000000203 mixture Substances 0.000 description 98
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 79
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 69
- 239000003921 oil Substances 0.000 description 69
- 239000012044 organic layer Substances 0.000 description 69
- 235000019198 oils Nutrition 0.000 description 68
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 67
- 239000012267 brine Substances 0.000 description 67
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 67
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 61
- 238000005160 1H NMR spectroscopy Methods 0.000 description 56
- 239000007832 Na2SO4 Substances 0.000 description 54
- 229910052938 sodium sulfate Inorganic materials 0.000 description 54
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 52
- 239000012043 crude product Substances 0.000 description 47
- 239000000741 silica gel Substances 0.000 description 46
- 229910002027 silica gel Inorganic materials 0.000 description 46
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 description 40
- 239000000460 chlorine Chemical group 0.000 description 35
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 30
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 239000000908 ammonium hydroxide Substances 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- 238000002953 preparative HPLC Methods 0.000 description 26
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 25
- 238000004587 chromatography analysis Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 22
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 15
- 230000004913 activation Effects 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 10
- 238000004020 luminiscence type Methods 0.000 description 10
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 238000004296 chiral HPLC Methods 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- XKEXJAUHJQAMSR-UHFFFAOYSA-N 3-methoxy-4-nitrobenzenethiol Chemical compound COC=1C=C(C=CC1[N+](=O)[O-])S XKEXJAUHJQAMSR-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- OAOPDYUHWPBJCW-UHFFFAOYSA-N cyanoboron;sodium Chemical compound [Na].[B]C#N OAOPDYUHWPBJCW-UHFFFAOYSA-N 0.000 description 7
- 125000001841 imino group Chemical group [H]N=* 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000001301 oxygen Chemical group 0.000 description 7
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- TYHYESDUJZRBKS-UHFFFAOYSA-N 2,3-dihydroindole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)CCC2=C1 TYHYESDUJZRBKS-UHFFFAOYSA-N 0.000 description 6
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 230000000155 isotopic effect Effects 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- RJGHQTVXGKYATR-UHFFFAOYSA-L dibutyl(dichloro)stannane Chemical compound CCCC[Sn](Cl)(Cl)CCCC RJGHQTVXGKYATR-UHFFFAOYSA-L 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QNRXNRGSOJZINA-MRVPVSSYSA-N (2r)-2,3-dihydro-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2N[C@@H](C(=O)O)CC2=C1 QNRXNRGSOJZINA-MRVPVSSYSA-N 0.000 description 3
- QNRXNRGSOJZINA-QMMMGPOBSA-N (2s)-2,3-dihydro-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2N[C@H](C(=O)O)CC2=C1 QNRXNRGSOJZINA-QMMMGPOBSA-N 0.000 description 3
- RDZFDWBNJDFXFN-UHFFFAOYSA-N 2-chloro-1-ethoxy-3-nitrobenzene Chemical compound CCOC1=CC=CC([N+]([O-])=O)=C1Cl RDZFDWBNJDFXFN-UHFFFAOYSA-N 0.000 description 3
- SKSRYWGHQFQRME-UHFFFAOYSA-N 2-methoxy-6-methylsulfanyl-3-nitropyridine Chemical compound COC1=NC(SC)=CC=C1[N+]([O-])=O SKSRYWGHQFQRME-UHFFFAOYSA-N 0.000 description 3
- VJPVZOFKLJOHII-UHFFFAOYSA-N 3-(bromomethyl)-7-chlorothieno[2,3-c]pyridine Chemical compound ClC1=NC=CC2=C1SC=C2CBr VJPVZOFKLJOHII-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- KGUOCLZDKIBCFN-UHFFFAOYSA-N 3-ethoxy-2-methoxyaniline Chemical compound CCOC1=CC=CC(N)=C1OC KGUOCLZDKIBCFN-UHFFFAOYSA-N 0.000 description 3
- ZUETWRPDKMAEIO-UHFFFAOYSA-N 3-methoxy-4-(prop-2-ynylamino)benzonitrile Chemical compound COc1cc(ccc1NCC#C)C#N ZUETWRPDKMAEIO-UHFFFAOYSA-N 0.000 description 3
- LCBUSDDLYBHQFA-UHFFFAOYSA-N 3-methoxy-4-nitrobenzonitrile Chemical compound COC1=CC(C#N)=CC=C1[N+]([O-])=O LCBUSDDLYBHQFA-UHFFFAOYSA-N 0.000 description 3
- ZWWLKHCHWPOZNU-UHFFFAOYSA-N 3-methyl-6-oxidothieno[2,3-c]pyridin-6-ium Chemical compound CC1=CSC2=C[N+](=CC=C21)[O-] ZWWLKHCHWPOZNU-UHFFFAOYSA-N 0.000 description 3
- LGDHBSXDQHCFFF-UHFFFAOYSA-N 3-methylthieno[2,3-c]pyridine Chemical compound N1=CC=C2C(C)=CSC2=C1 LGDHBSXDQHCFFF-UHFFFAOYSA-N 0.000 description 3
- SCXGWOFGMVEUGW-UHFFFAOYSA-N 4-amino-3-methoxybenzonitrile Chemical compound COC1=CC(C#N)=CC=C1N SCXGWOFGMVEUGW-UHFFFAOYSA-N 0.000 description 3
- JXQNQTASCDHMIL-UHFFFAOYSA-N 4-bromo-2-methoxy-3-(trifluoromethyl)aniline Chemical compound COC1=C(N)C=CC(Br)=C1C(F)(F)F JXQNQTASCDHMIL-UHFFFAOYSA-N 0.000 description 3
- VDWHHDSTRVJNJW-UHFFFAOYSA-N 4-dimethylphosphoryl-2-nitroaniline Chemical compound CP(C)(=O)c1ccc(N)c(c1)[N+]([O-])=O VDWHHDSTRVJNJW-UHFFFAOYSA-N 0.000 description 3
- IYZHUTZFTQZGIZ-UHFFFAOYSA-N 4-iodo-1-benzofuran-7-amine Chemical compound NC1=CC=C(I)C2=C1OC=C2 IYZHUTZFTQZGIZ-UHFFFAOYSA-N 0.000 description 3
- JLHSWJPUDDAHMN-UHFFFAOYSA-N 7-chloro-3-methylthieno[2,3-c]pyridine Chemical compound N1=CC=C2C(C)=CSC2=C1Cl JLHSWJPUDDAHMN-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 210000003771 C cell Anatomy 0.000 description 3
- YXFAOWYMDGUFIQ-FIBGUPNXSA-N C(OC1=NC=CC=C1N)([2H])([2H])[2H] Chemical compound C(OC1=NC=CC=C1N)([2H])([2H])[2H] YXFAOWYMDGUFIQ-FIBGUPNXSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DHCAVCFMNVWXMV-UHFFFAOYSA-N NC1=CC=C(Br)N=C1C#N Chemical compound NC1=CC=C(Br)N=C1C#N DHCAVCFMNVWXMV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- GRPOFAKYHPAXNP-MRVPVSSYSA-N [(2r)-2,3-dihydro-1h-indol-2-yl]methanol Chemical compound C1=CC=C2N[C@@H](CO)CC2=C1 GRPOFAKYHPAXNP-MRVPVSSYSA-N 0.000 description 3
- GRPOFAKYHPAXNP-QMMMGPOBSA-N [(2s)-2,3-dihydro-1h-indol-2-yl]methanol Chemical compound C1=CC=C2N[C@H](CO)CC2=C1 GRPOFAKYHPAXNP-QMMMGPOBSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 230000007257 malfunction Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000011574 phosphorus Chemical group 0.000 description 3
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010060971 Astrocytoma malignant Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical class CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000111 isothermal titration calorimetry Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JZNWQLLPLOQGOI-UHFFFAOYSA-N tert-butyl 3-fluoro-4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C(F)C1 JZNWQLLPLOQGOI-UHFFFAOYSA-N 0.000 description 2
- KAJZZLBZXOBEMD-UHFFFAOYSA-N tert-butyl n-chlorosulfonylcarbamate Chemical compound CC(C)(C)OC(=O)NS(Cl)(=O)=O KAJZZLBZXOBEMD-UHFFFAOYSA-N 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JFVLNTLXEZDFHW-MRVPVSSYSA-N (2r)-2-azaniumyl-3-(2-bromophenyl)propanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CC1=CC=CC=C1Br JFVLNTLXEZDFHW-MRVPVSSYSA-N 0.000 description 1
- JFVLNTLXEZDFHW-QMMMGPOBSA-N (2s)-2-amino-3-(2-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1Br JFVLNTLXEZDFHW-QMMMGPOBSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- ZZRFDLHBMBHJTI-UHFFFAOYSA-N 1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1C1OCCCC1 ZZRFDLHBMBHJTI-UHFFFAOYSA-N 0.000 description 1
- ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 description 1
- YYWJHOJMCOIVNS-UHFFFAOYSA-N 1-benzofuran-7-amine Chemical compound NC1=CC=CC2=C1OC=C2 YYWJHOJMCOIVNS-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- RVPBBFKWSJLAPD-UHFFFAOYSA-N 1-fluoro-2-methoxy-3-nitrobenzene Chemical compound COC1=C(F)C=CC=C1[N+]([O-])=O RVPBBFKWSJLAPD-UHFFFAOYSA-N 0.000 description 1
- BLRLPMIRFPMIFG-UHFFFAOYSA-N 1-methylpiperidin-3-one;hydrochloride Chemical compound [Cl-].C[NH+]1CCCC(=O)C1 BLRLPMIRFPMIFG-UHFFFAOYSA-N 0.000 description 1
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- CZSXIGLHRRJGPZ-UHFFFAOYSA-N 1-oxothian-4-one Chemical compound O=C1CCS(=O)CC1 CZSXIGLHRRJGPZ-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- HEZIOZBMPKPOER-UHFFFAOYSA-N 2,3-dimethoxyaniline Chemical compound COC1=CC=CC(N)=C1OC HEZIOZBMPKPOER-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LTAUXXMHNXMZJB-UHFFFAOYSA-N 2-amino-5-bromo-3-methoxybenzonitrile Chemical compound COC1=CC(Br)=CC(C#N)=C1N LTAUXXMHNXMZJB-UHFFFAOYSA-N 0.000 description 1
- OATYCBHROMXWJO-UHFFFAOYSA-N 2-amino-5-bromobenzonitrile Chemical compound NC1=CC=C(Br)C=C1C#N OATYCBHROMXWJO-UHFFFAOYSA-N 0.000 description 1
- QBGLHYQUZJDZOO-UHFFFAOYSA-N 2-chloro-3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1Cl QBGLHYQUZJDZOO-UHFFFAOYSA-N 0.000 description 1
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 1
- QOMZMKOUJOLVKC-UHFFFAOYSA-N 2-methoxy-3-(trifluoromethyl)aniline Chemical compound COC1=C(N)C=CC=C1C(F)(F)F QOMZMKOUJOLVKC-UHFFFAOYSA-N 0.000 description 1
- FMLJHAHJVYPRAV-UHFFFAOYSA-N 2-methoxy-3-methylaniline Chemical compound COC1=C(C)C=CC=C1N FMLJHAHJVYPRAV-UHFFFAOYSA-N 0.000 description 1
- GVBHRNIWBGTNQA-UHFFFAOYSA-N 2-methoxy-4-nitroaniline Chemical compound COC1=CC([N+]([O-])=O)=CC=C1N GVBHRNIWBGTNQA-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- POVDLRLOSUDCMI-UHFFFAOYSA-N 3,3,3-trifluoroprop-1-en-2-ylboronic acid Chemical compound OB(O)C(=C)C(F)(F)F POVDLRLOSUDCMI-UHFFFAOYSA-N 0.000 description 1
- DNNVRTZJRKIUFK-UHFFFAOYSA-N 3,4-dihydroquinoline Chemical compound C1=CC=C2N=CCCC2=C1 DNNVRTZJRKIUFK-UHFFFAOYSA-N 0.000 description 1
- KMHCTFSFWQRZTR-UHFFFAOYSA-N 3-aminopyridine-2-carbonitrile Chemical compound NC1=CC=CN=C1C#N KMHCTFSFWQRZTR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IWWBQKIYIIAKMF-UHFFFAOYSA-N 3-bromo-7-nitro-1-benzothiophene Chemical compound [O-][N+](=O)C1=CC=CC2=C1SC=C2Br IWWBQKIYIIAKMF-UHFFFAOYSA-N 0.000 description 1
- SZTIZZFKWQWSSP-UHFFFAOYSA-N 3-bromooxetane Chemical compound BrC1COC1 SZTIZZFKWQWSSP-UHFFFAOYSA-N 0.000 description 1
- YTWCEXXHTNFGKR-UHFFFAOYSA-N 3-bromothieno[2,3-c]pyridine Chemical compound N1=CC=C2C(Br)=CSC2=C1 YTWCEXXHTNFGKR-UHFFFAOYSA-N 0.000 description 1
- FJLIZBBURXQODR-UHFFFAOYSA-N 3-fluoro-1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(F)(C(O)=O)C1 FJLIZBBURXQODR-UHFFFAOYSA-N 0.000 description 1
- OZXCOGPRBUSXLE-UHFFFAOYSA-N 3-fluoro-4-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(C#N)C=C1F OZXCOGPRBUSXLE-UHFFFAOYSA-N 0.000 description 1
- HHTYEQWCHQEJNV-UHFFFAOYSA-N 4-bromo-2-iodoaniline Chemical compound NC1=CC=C(Br)C=C1I HHTYEQWCHQEJNV-UHFFFAOYSA-N 0.000 description 1
- ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 1
- IVBVKTPDEWDNRW-UHFFFAOYSA-N 4-bromooxane Chemical compound BrC1CCOCC1 IVBVKTPDEWDNRW-UHFFFAOYSA-N 0.000 description 1
- WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- ZPJBSWJZELXZKA-UHFFFAOYSA-N 7-amino-2,3-dihydroisoindol-1-one Chemical compound NC1=CC=CC2=C1C(=O)NC2 ZPJBSWJZELXZKA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 238000012287 DNA Binding Assay Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- SQYRHQWZELBKKI-UHFFFAOYSA-N FC1=CC=C(C(=N1)OC)[N+](=O)[O-] Chemical compound FC1=CC=C(C(=N1)OC)[N+](=O)[O-] SQYRHQWZELBKKI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010063916 Metastatic gastric cancer Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PPDJNZTUDFPAHX-UHFFFAOYSA-N benzyltrimethylammonium dichloroiodate Chemical compound Cl[I-]Cl.C[N+](C)(C)CC1=CC=CC=C1 PPDJNZTUDFPAHX-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 238000003738 britelite plus Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000004427 diamine group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- YHEBUXDOUNWVNZ-UHFFFAOYSA-M diphenyl(trifluoromethyl)sulfanium;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.C=1C=CC=CC=1[S+](C(F)(F)F)C1=CC=CC=C1 YHEBUXDOUNWVNZ-UHFFFAOYSA-M 0.000 description 1
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 125000005485 noradamantyl group Chemical group 0.000 description 1
- 125000002872 norbornadienyl group Chemical group C12=C(C=C(CC1)C2)* 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 208000012988 ovarian serous adenocarcinoma Diseases 0.000 description 1
- 201000003709 ovarian serous carcinoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- OCWBJZCKQBCSPB-UHFFFAOYSA-N spiro[2h-isoindole-3,1'-cyclopropane]-1-one Chemical compound C12=CC=CC=C2C(=O)NC21CC2 OCWBJZCKQBCSPB-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- HPHVNLXMQXEDFX-UHFFFAOYSA-N tert-butyl 3-fluoro-4-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)C(=O)C1 HPHVNLXMQXEDFX-UHFFFAOYSA-N 0.000 description 1
- GRSPYCFNEDACGF-UHFFFAOYSA-N tert-butyl 4-fluoro-4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(F)(C=O)CC1 GRSPYCFNEDACGF-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- BDCUDAOHXKZZAJ-UHFFFAOYSA-N tricyclopropylbismuthane Chemical compound C1CC1[Bi](C1CC1)C1CC1 BDCUDAOHXKZZAJ-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Definitions
- the present invention relates to compounds targeting p53 mutants, pharmaceutical compositions comprising the compounds, methods of preparing the compounds and methods of using the compounds to prevent or treat a disease or condition related to p53 mutants.
- the p53 protein referred to as the “guardian of the human genome” is a tetrameric transcription factor that prevents mutation to the genome by regulating the expression of a subgroup of target genes. Although biologically active as a homotetramer, each p53 monomer is comprised of 393 amino acids, and is divided into five key regulatory domains: the transactivation domain (TAD) , proline-rich region (PR) , the DNA binding domain (DBD) , the oligomerization domain (OD) , and the C-terminus.
- TAD transactivation domain
- PR proline-rich region
- DBD DNA binding domain
- OD oligomerization domain
- C-terminus the C-terminus
- the p53 protein Under normal conditions, the p53 protein has a “cancer suppressor” effect but p53 is unstable, with a half-life ranging from 5 to 30 minutes. Activation of p53 initiates pathways involved in apoptosis, DNA repair, cell cycle arrest, anti-angiogenesis, and senescence in order to avoid propagation of damaged cells. p53 activation occurs via a complicated regulatory network composed of three key steps: (1) p53 stabilization by phosphorylation, (2) DNA binding, and (3) target gene activation.
- mutant p53 is the most frequently mutated protein in human cancer. As examples, mutations are present in 96%of ovarian serous carcinomas, 87%of metastatic gastric cancers, 85%of small cell lung cancers, and 75%of pancreatic cancers, and are also associated with worsened prognosis and patient survival. Further, mutant p53 is a highly abundant and tumour-specific target as it is typically overexpressed in cancer, partly as a result of its inability to induce MDM2 gene expression in order to establish a negative feedback loop to control p53 expression. As a result of its overexpression, mutant p53 also possesses toxic GoF properties that can propagate and cause malfunctions to other important proteins and pathways that regulate the cell cycle.
- mutant p53 represents an important pharmacological target and the past two decades have seen considerable dedication to the development of small molecules that aim to restore wild-type function in mutant p53.
- targeting mutant p53 means to more selectively target the cancer cells, reducing the risk of side effects and toxicity towards healthy tissues.
- numerous mechanistic strategies have been developed including protein refolding via cysteine modification, protein stabilization, modulation of protein aggregation, and zinc chelation.
- P53 is inactivated directly by mutation in 50%of human cancers (ranging from about 1%to 85%depending on the type of cancer) , and almost all cancers exhibit malfunction along the p53 pathway.
- the frequency and aggressive nature of cancers exhibiting p53 malfunction has driven a widespread effort both in academia and the pharmaceutical industry to restore normal p53 expression and activity over the past decades. While this approach is faced with significant challenges including frequent off-target mechanisms of action, major technological advancements in gene sequencing capability and a shift towards personalized medicine holds significant promise for the development of small molecules capable of mutant-specific p53 reactivation.
- Mutations in p53 located in the DNA binding domain of the protein or periphery of the DNA-binding surface result in aberrant protein folding required for DNA recognition and binding. Mutations in p53 can occur, for example, at amino acids Val143, His168, Arg175, Tyr220, Gly245, Arg248, Arg249, Phe270, Arg273, and Arg282.
- P53 mutations that can abrogate the activity of p53 include, for example, R175H, Y220C, G245S, R248Q, R248W, R273H, and R282W. These p53 mutations can either distort the structure of the DNA-binding site or thermodynamically destabilize the folded protein at body temperature. Wild-type function of p53 mutants can be recovered by binding of the p53 mutant to a compound that can shift the folding-unfolding equilibrium towards the folded state, thereby reducing the rate of unfolding and destabilization.
- the p53 Y220C mutation is associated with many cancers, e.g., breast cancer, non-small cell lung cancer, colorectal cancer, pancreatic cancer, and ovarian cancer.
- PC14586 was reported to be a small molecule reactivator targeting p53 Y220C mutant developed by PMV Pharmaceuticals, Inc., there is still a critical need in the art for the development of new small molecule reactivators targeting p53 mutants (e.g., Y220C mutant) with high specificity and activity as well as low toxicity.
- it is an object of the present invention to provide a pharmaceutical composition comprising the above-mentioned compound targeting mutant p53.
- the present disclosure further provides the following aspect.
- a compound of formula (I) or a stereoisomer, tautomer, deuterated derivative, prodrug or pharmaceutically acceptable salt thereof:
- one of X 1 , X 2 , X 3 and X 4 is selected from N or CR 2 , and the others of X 1 , X 2 , X 3 and X 4 are each independently selected from N or CR 4 ;
- X 5 is selected from N or CR 1 ;
- E is selected from alkylene, alkenylene or alkynylene
- R 1 is independently selected from hydrogen, deuterium, halogen, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -CN, -OR’ , -SR’ , -C (O) R’ , -C (O) N (R’ ) 2 , -C (O) OR’ , -OC (O) R’ , -OC (O) N (R’ ) 2 , -N (R’ ) 2 , -NR’ C (O) R’ , -NR’ C (O) OR’ , -NR’ C (O) N (R’ ) 2 , -S (O) R’ , -S (O) N (R’ ) 2 , -NR’S (O) R’ , -NR’S (O) N (R’ ) 2 , -NR’S (O) R’ , -
- R 2 is -NR 51 R 52 , -OR 53 or -SR 54 ;
- R 3 is selected from hydrogen, deuterium, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -C (O) R’ , -C (O) N (R’ ) 2 , -C (O) OR’ , -S (O) R’ , -S (O) N (R’ ) 2 , -S (O) 2 R’ , -S (O) 2 N (R’ ) 2 , -PO (R’ ) 2 , 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, 5-12 membered heteroaryl; said -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C
- each R 3a is independently selected from deuterium, halogen, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -CN, oxo, -OR’ , -SR’ , -C (O) R’ , -C (O) N (R’ ) 2 , -C (O) OR’ , -OC (O) R’ , -OC (O) N (R’ ) 2 , -N (R’ ) 2 , -NR’ C (O) R’ , -NR’ C (O) OR’ , -NR’ C (O) N (R’ ) 2 , -S (O) R’ , -S (O) N (R’ ) 2 , -NR’S (O) R’ , -NR’S (O) N (R’ ) 2 , -NR’S (O) R
- each R 3b is independently selected from deuterium, halogen, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -CN, oxo, -OR’ , -SR’ , -C (O) R’ , -C (O) N (R’ ) 2 , -C (O) OR’ , -OC (O) R’ , -OC (O) N (R’ ) 2 , -N (R’ ) 2 , -NR’ C (O) R’ , -NR’ C (O) OR’ , -NR’ C (O) N (R’ ) 2 , -S (O) R’ , -S (O) N (R’ ) 2 , -NR’S (O) R’ , -NR’S (O) N (R’ ) 2 , -NR’S (O) R
- R 4 at each occurrence is independently selected from hydrogen, deuterium, halogen, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -CN, -OR’ , -SR’ , -C (O) R’ , -C (O) N (R’ ) 2 , -C (O) OR’ , -OC (O) R’ , -OC (O) N (R’ ) 2 , -N (R’ ) 2 , -NR’ C (O) R’ , -NR’ C (O) OR’ , -NR’ C (O) N (R’ ) 2 , -S (O) R’ , -S (O) N (R’ ) 2 , -NR’S (O) R’ , -NR’S (O) N (R’ ) 2 , -NR’S (O) R’
- R 51 , R 52 , R 53 and R 54 are each independently selected from hydrogen, deuterium, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -C (O) R’ , -C (O) N (R’ ) 2 , -C (O) OR’ , -S (O) R’ , -S (O) N (R’ ) 2 , -S (O) 2 R’ , -S (O) 2 N (R’ ) 2 , -PO (R’ ) 2 , 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, 5-12 membered heteroaryl, or -C 1-6 alkyl-C 3-12 heterocycloalkyl; said
- R 11 and R 12 are independently selected from hydrogen, deuterium, -OH, halogen, -CN, oxo, -C 1-6 alkyl, -C 1-6 haloalkyl, -C 1-6 alkoxy, -NH 2 , -NHC 1-6 alkyl, -N (C 1-6 alkyl) 2 or 3-6 membered cycloalkyl; wherein said -C 1-6 alkyl, -C 1-6 alkoxy and 3-6 membered cycloalkyl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, -OH, halogen, -CN, oxo, -C 1-6 alkoxy, -NH-C 1-6 alkyl, -N (C 1-4 alkyl) 2 , or 3-6 membered cycloalkyl; or
- R 11 or R 12 and R 3 together with atoms to which they are respectively attached form a ring, such as, monocyclic, bicyclic, or polycyclic 3-12 membered alicyclic group, 3-12 membered heterocyclyl, 6-12 membered aryl, or 5-12 membered heteroaryl, which ring is independently optionally substituted with one or more R 3a ;
- R 13 is selected from hydrogen, deuterium, -C 1-6 alkyl or 3-6 membered cycloalkyl; wherein said -C 1-6 alkyl and 3-6 membered cycloalkyl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, -OH, halogen, -CN, oxo, -C 1-6 alkoxy, -NH 2 , -NHC 1-6 alkyl, or -N (C 1-4 alkyl) 2 ; or
- R 3 and R 13 together with the nitogen atom to which they are attached form a ring, such as, monocyclic, bicyclic, or polycyclic 3-12 membered alicyclic group, 3-12 membered heterocyclyl, 6-12 membered aryl, or 5-12 membered heteroaryl, which ring is independently optionally substituted with one or more R 3a ;
- each R’ at each occurrence is independently selected from hydrogen, deuterium, halogen, -OH, -CN, oxo, -NH 2 , -NHC 1-6 alkyl, -N (C 1-6 alkyl) 2 , -C 1-6 alkyl, -C 1-6 alkylOC 1-6 alkyl, -C 1-6 alkyl-NHC 1-6 alkyl, -C 1-6 alkyl-N (C 1-6 alkyl) 2 , -C 1-6 haloalkyl, -OC 1-6 alkyl, -C (O) OC 1-6 alkyl, -C 3-14 cycloalkyl, -C 3-14 heterocycloalkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, 6-12 membered aryl, or 5-12 membered heteroaryl; wherein said -C 1-6 alkyl, -OC 1-6 alkyl, -C 3-14 cyclo
- heterocycloalkyl, heterocycloalkenyl, and heteroaryl each independently contains 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O, P or S;
- n is selected from 1, 2, 3, 4, 5 or 6.
- X 2 , X 3 , and X 4 in the formula (I-1) are each independently selected from N or CR 4 ;
- X 2 is independently selected from N or CR 4 .
- R 1 is independently selected from halogen, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -CN, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-10 membered aryl, or 5-12 membered heteroaryl, said -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-10 membered aryl, and 5-12 membered heteroaryl are independently optionally
- R 1 is independently selected from -F, -Cl, -C 1-3 alkyl, -C 2-4 alkenyl, -C 2-4 alkynyl, -C 1-3 haloalkyl, -CN, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered aryl, 5-12 membered heteroaryl, said -C 1-3 alkyl, -C 2-4 alkenyl, -C 2-4 alkynyl, -C 1-3 haloalkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered aryl, and 5-12 membered heteroaryl are independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from -F, -Cl, -OH, -C 1-3 alkyl, -C 2-4 alkenyl, -C 2-4 alkyn
- R 1 is independently selected from -F, -Cl, -C 1-3 alkyl, -C 1-3 haloalkyl, 3-6 membered cycloalkyl, 5 membered heteroaryl containing 1 or 2 heteroatoms selected from N, O or S, or 6 membered heteroaryl containing 1 or 2 heteroatoms selected from N; said -C 1-3 alkyl, -C 1-3 haloalkyl, 3-6 membered cycloalkyl, 5 membered heteroaryl and 6 membered heteroaryl are each independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents selected from -F, -OH, -C 1-3 alkyl, -OC 1-3 alkyl, -NH 2 , -NHC 1-3 alkyl, -N (C 1-3 alkyl) 2 , -CN or 3-6 membered cycloalkyl.
- R 1 is independently selected from -C 1-3 alkyl, -C 1-3 haloalkyl, or 5 membered heteroaryl containing 1 or 2 heteroatoms selected from N, O or S; and R 1 is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents selected from -F, -OH, -OC 1-3 alkyl, -NH 2 , -NHC 1-3 alkyl, -N (C 1-3 alkyl) 2 , -CN or 3-6 membered cycloalkyl.
- R 51 is selected from -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -C (O) R’ , -C (O) N (R’ ) 2 , -C (O) OR’ , 3-6 membered cycloalkyl, 3-10 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl or -C 1-6 alkyl-C 3-12 heterocycloalkyl; said -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, 3-6 membered cycloalkyl, 3-10 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl and -C 3-12 heterocycloalkyl are each independently optionally substituted with one
- R 51 is selected from 8 membered bridged heterocyclyl, -C (O) -C 3-5 heterocycloalkyl, or -C 1-3 alkyl-C 3-5 heterocycloalkyl, said 8 membered bridged heterocyclyl, -C 1-3 alkyl or -C 3-5 heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, or 6 R 5e ;
- R 5a , R 5c and R 5d are each independently selected from hydrogen; -C 1-6 alkyl; or -C 1-6 alkyl substituted with 1, 2, 3, 4, 5 or 6 substituents selected from -F, -C 1-3 alkyl, oxo, -OC 1-3 alkyl, -NH 2 , -NHC 1-3 alkyl, -N (C 1-3 alkyl) 2 , -CN or 3-6 membered cycloalkyl;
- R 5b and R 5e are each independently selected from -F, -C 1-6 alkyl, oxo, -OC 1-6 alkyl, -NH 2 , -NHC 1-6 alkyl, -N (C 1-6 alkyl) 2 , -CN or 3-6 membered cycloalkyl, wherein, said -C 1-6 alkyl is optionally substituted with 1, 2, 3 or 4 substituents selected from -F, -C 1-3 alkyl, oxo, -OC 1-3 alkyl, -NH 2 , -NHC 1-3 alkyl, -N (C 1-3 alkyl) 2 , -CN or 3-6 membered cycloalkyl.
- R 3 is independently selected from 3-12 membered heterocycloalkenyl, 6-10 membered aryl, or 5-12 membered heteroaryl; said 3-12 membered heterocycloalkenyl, 6-10 membered aryl, or 5-12 membered heteroaryl at each occurrence is independently optionally substituted with one or more R 3a substituents selected from halogen, NH 2 , NH-C 1-6 alkyl, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -CN, -NO 2 , -OR’ , -SR’ , -C (O) R’ , oxo, -C (O) N (R’ ) 2 , -C (O) OR’ , -OC (O) R’ , -N (R’ ) 2 , -NR’ C
- R 11 or R 12 is hydrogen or oxo; or R 11 or R 12 and R 3 together with atoms to which they are respectively attached form 5-12 membered heterocyclyl, preferably indolinyl, optionally substituted with one or more R 3a .
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) , or a stereoisomer, tautomer, deuterated derivative, prodrug or pharmaceutically acceptable salt thereof according to any one of items 1-22, and a pharmaceutically acceptable carrier, diluent, or excipient.
- a compound of formula (I) or a stereoisomer, tautomer, deuterated derivative, prodrug or pharmaceutically acceptable salt thereof according to any one of items 1-22, or a pharmaceutical composition according to item 23 for use in the prevention or treatment of a disease or condition related to p53 mutant protein in a subject.
- a method for preventing or treating a disease or condition related to p53 mutant protein in a subject comprising administering to a subject a therapeutically effective amount of a compound of formula (I) , or a stereoisomer, tautomer, deuterated derivative, prodrug or pharmaceutically acceptable salt thereof according to any one of items 1-22, or a pharmaceutical composition according to item 23.
- the present invention provides compounds, compositions and methods for restoring wild-type function of mutant p53.
- the compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA.
- the restoration of activity of the p53 mutant can allow for the activation of downstream effectors of p53 leading to inhibition of cancer progression.
- the present invention further provides a method for treating a disease or condition related to p53 mutant protein. There is also provided a method for preparation of a compound of the present invention.
- the compounds of the present invention can selectively bind to a p53 mutant and can recover wild-type activity of the p53 mutant including, for example, DNA binding function and activation of downstream targets involved in tumor suppression.
- a compound of the invention selectively binds to the p53 Y220C mutant.
- the Y220C mutant is a temperature sensitive mutant, which binds to DNA at lower temperature and is denatured at body temperature.
- a compound of the invention can selectively bind to the p53 Y220Cs and stabilize the Y220C mutant to reduce the likelihood of denaturation of the protein at body temperature.
- assays can be utilized to detect, for example, a conformational change in the p53 mutant or activation of wild-type p53 targets.
- Conformational changes in p53 can be measured by, for example, differential scanning fluorimetry (DSF) , isothermal titration calorimetry (ITC) , nuclear magnetic resonance spectrometry (NMR) , or X-ray crystallography.
- DFS differential scanning fluorimetry
- ITC isothermal titration calorimetry
- NMR nuclear magnetic resonance spectrometry
- antibodies specific for the wild type of mutant conformation of p53 can be used to detect a conformational change via, for example, immunoprecipitation (IP) , immunofluorescence (IF) , or immunoblotting.
- IP immunoprecipitation
- IF immunofluorescence
- Methods used to detect the ability of the p53 mutant to bind DNA can include, for example, DNA affinity immunoblotting, modified enzyme-linked immunosorbent assay (ELISA) , electrophoretic mobility shift assay (EMSA) , fluorescence resonance energy transfer (FRET) , homogeneous time-resolved fluorescence (HTRF) , and a chromatin immunoprecipitation (ChIP) assay.
- DNA affinity immunoblotting DNA affinity immunoblotting
- ELISA modified enzyme-linked immunosorbent assay
- EMSA electrophoretic mobility shift assay
- FRET fluorescence resonance energy transfer
- HTRF homogeneous time-resolved fluorescence
- ChIP chromatin immunoprecipitation
- Activation of p53 effector proteins can be detected by, for example, immunohistochemistry (IHC-P) , reverse transcription polymerase chain reaction (RT-PCR) , and western blotting.
- IHC-P immunohistochemistry
- RT-PCR reverse transcription polymerase chain reaction
- the activation of p53 can also be measured by the induction of apoptosis via the caspase cascade and using methods including, for example, Annexin V staining, TUNEL assays, pro-caspase and caspase levels, and cytochrome c levels.
- Another consequence of p53 activation is senescence, which can be measured using methods such as ⁇ -galactosidase staining.
- the terms “include” and “including” have the same meaning as the terms “comprise” and “comprising” in that these latter terms are “open” transitional terms that do not limit claims only to the recited elements succeeding these transitional terms.
- C 1-6 alkyl refers to an alkyl group as defined hereinafter having 1 to 6 carbon atoms in total
- C 3-8 cycloalkyl refers to a cycloalkyl group as defined hereinafter having 3 to 8 carbon atoms in total
- C 6-10 aryl refers to an aryl group as defined hereinafter having 6 to 10 carbon atoms in total.
- Carbon atoms that may exist in the substituents of the chemical group are not included in the total number of carbon atoms in the shorthand notation.
- arylalkyl means that the aryl group is attached to the rest of the molecule via the alkyl group
- alkoxyl means that the aliphatic group is attached to the rest of the molecule via an oxy group
- alkyl optionally substituted by one or more means the alkyl group is unsubstituted or substituted by one or more (such as 1, 2, 3, 4, 5 or 6) halogens, and that the description includes both substituted alkyl groups and unsubstituted alkyl groups.
- substituted means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded.
- substituted refers to any level of substitution, e.g., mono-, di-, tri-, tetra-or penta-substitution, where such substitution is permitted.
- the substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule.
- the term “substituted” is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
- the permissible substituents can be one or more and the same or different for appropriate organic compounds.
- the phrase "optionally substituted” means unsubstituted or substituted.
- substituted means that a hydrogen atom is removed and replaced by a substituent.
- a single divalent substituent e.g., oxo, can replace two hydrogen atoms.
- stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures. All the stereoisomers of the invention can be identified and determined by conventional X-ray single crystal diffraction analysis. The present invention contemplates various stereoisomers and mixtures thereof.
- the prefixes D and L, or R and S are used to denote the absolute configuration of the molecule about its chiral center (s) .
- the pre fixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory.
- a compound prefixed with (+) or d is dextrorotatory.
- these stereoisomers are identical except that they are mirror images of one another.
- a spec ific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiom eric mixture.
- a 50: 50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur w here there has been no stereoselection or stereospecificity in a chemical reaction or process.
- the terms “racemic mix ture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
- tautomer refers to an isomer resulted from a proton shift from one atom of a molecule to another atom of the same molecule. All tautomeric forms of the compound of formula (I) of the present invention are included within the scope of the present invention.
- structures depicted herein are also meant to include all isomeric forms of the structure, e.g., racemic mixtures, cis/trans isomers, geometric (or conformational) isomers, such as (Z) and (E) isomers.
- geometric (or conformational) isomers such as (Z) and (E) isomers.
- the compound having a double bond or cycle in the present application includes both E-and Z-geometric isomers.
- isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention and their uses.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I or 125 I.
- isotopes of hydrogen include deuterium and tritium.
- the isotopes of hydrogen can be denoted as 1 H (hydrogen) , 2 H (deuterium) and 3 H (tritium) . They are also commonly denoted as D for deuterium and T for tritium.
- CD 3 denotes a methyl group wherein all of the hydrogen atoms are deuterium.
- Isotopes of carbon include 13 C and 14 C. Isotopically labeled compounds of the present disclosure are equivalent to those unlabeled, for example, deuterated compounds of the present disclosure are equivalent to those non-deuterated.
- Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent.
- deuterated derivative refers to a compound having the same chemical structure as a reference compound, but with one or more hydrogen atoms replaced by a deuterium atom ( “D” or “ 2 H” ) . It will be recognized that some variation of natural isotopic abundance occurs in a synthesized compound depending on the origin of chemical materials used in the synthesis. Notwithstanding this variation, the concentration of naturally abundant stable hydrogen isotopes is small and immaterial as compared to the degree of stable isotopic substitution of deuterated derivatives described herein.
- the deuterated derivatives disclosed herein have an isotopic enrichment factor for each deuterium atom, of at least 3500 (52.5%deuterium incorporation at each designated deuterium) , at least 4500 (67.5%deuterium incorporation at each designated deuterium) , at least 5000 (75%deuterium incorporation at each designated deuterium) , at least 5500 (82.5%deuterium incorporation at each designated deuterium) , at least 6000 (90%deuterium incorporation at each designated deuterium) , at least 6333.3 (95%deuterium incorporation at each designated deuterium) , at least 6466.7 (97%deuterium incorporation at each designated deuterium) , or at least 6600 (99%deuterium incorporation at
- amino refers to the -NH 2 group.
- cyano refers to the -CN group.
- nitro refers to the -NO 2 group.
- halogen as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo.
- the preferred halogen groups include -F, -Cl and -Br.
- alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched.
- alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl.
- C 1-6 as in C 1-6 alkyl is defined to identify the group as having 1, 2, 3, 4, 5 or 6 carbon atoms in a linear or branched arrangement.
- alkenyl means a straight or branch-chained hydrocarbon radical containing one or more (such as 1, 2, 3, 4, 5 or 6) double bonds and typically from 2 to 20 carbon atoms in length.
- C 2-6 alkenyl contains from 2 to 6 carbon atoms.
- Alkenyl group include, but are not limited to, for example, ethenyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, hepetenyl, octenyl and the like.
- alkynyl contains a straight or branch-chained hydrocarbon radical containing one or more (such as 1, 2, 3, 4, 5 or 6) triple bonds and typically from 2 to 20 carbon atoms in length.
- C 2-6 alkynyl contains from 2 to 6 carbon atoms.
- Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
- alkoxyl radicals are oxygen ethers formed from the previously described alkyl groups.
- a “cycloalkyl” is a cyclic hydrocarbon which is completely saturated. “cycloalkyl” includes monocyclic and bicyclic rings. Typically, a monocyclic cycloalkyl has from 3 to about 12 carbon atoms, more typically 3 to 8 carbon atoms unless otherwise defined, examplary “cycloalkyl” groups includes but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and so on. Cycloalkyl includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings.
- spirocyclic cycloalkyl refers to a bicyclic cycloalkyl in which each of the rings shares one adjacent atom with the other ring.
- fused cycloalkyl refers to a bicyclic cycloalkyl in which each of the rings shares two adjacent atoms with the other ring.
- bridged cycloalkyl refers to a cycloalkyl that includes at least two bridgehead carbon atoms and at least one bridging carbon atom.
- bridged cycloalkyl includes “bicyclic bridged cycloalkyls” which includes two bridgehead carbon atoms and “polycyclic bridged cycloalkyls” which includes more than two bridgehead carbon atoms.
- Typical bridged cycloalkyls include, but are not limited to adamantyl, noradamantyl, bicyclo [1.1.0] butanyl, norboranyl (bicyclo [2.2.1] heptanyl) , norbornenyl (bicyclo [2.2. l] heptanyl) , norbornadienyl (bicyclo [2.2.
- cycloalkenyl refers to a partially unsaturated cyclic hydrocarbon group containing 1 to 4 rings and 3 to 8 carbons per ring system. Exemplary such groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, etc. “cycloalkenyl” includes monocyclic, bicyclic, tricyclic, or tetracyclic ring system in which one, two, three or more atoms are shared between the two rings. The term “spirocyclic cycloalkenyl” refers to a bicyclic cycloalkenyl in which each of the rings shares one adjacent atom with the other ring.
- fused cycloalkenyl refers to a polycyclic cycloalkenyl in which two rings shares two adjacent atoms.
- bridged cycloalkenyl refers to a cycloalkenyl that includes at least two bridgehead atoms and at least one bridging atom. “bridged cycloalkenyl” includes “bicyclic bridged cycloalkenyl” which includes two bridgehead atoms and “polycyclic bridged cycloalkenyl” which includes more than two bridgehead atoms.
- heterocycloalkyl refers to a stable 3-18 membered non-aromatic ring radical completely saturated that comprises two to twelve carbon atoms and from one to six heteroatoms selected from such as nitrogen, oxygen, phosphorus and sulfur. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system.
- spirocyclic heterocycloalkyl or “spiro-heterocyclyl” refers to a polycyclic heterocycloalkyl in which two rings shares one atom.
- fused heterocycloalkyl refers to a polycyclic heterocycloalkyl in which two rings shares two adjacent atoms.
- bridged heterocycloalkyl or “bridged-heterocyclyl” refers to a heterocycloalkyl that includes at least two bridgehead atoms and at least one bridging atom.
- Bridged heterocycloalkyl or “bridged-heterocyclyl” includes “bicyclic bridged heterocycloalkyl” which includes two bridgehead atoms and “polycyclic bridged heterocycloalkyl” which includes at least two bridgehead atoms.
- the heteroatoms in the heterocycloalkyl radical are optionally oxidized.
- the heterocycloalkyl is attached to the rest of the molecule through any atom of the ring (s) .
- heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl [1, 3] dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl octahydroisoindoly, 2-oxopiperazinyl, 2-oxopiperidiny1, 2-oxopyrrolidinyl, oxazolidinyl, piperidnyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, te
- heterocycloalkenyl refers to the above-mentioned hererocycloalkyl having at least one double bond.
- a heterocycloalkenyl may be a single ring or multiple rings wherein the multiple rings include “spirocyclic heterocycloalkenyl” , “fused heterocycloalkenyl” , and “bridged heterocycloalkenyl” .
- “Spirocyclic heterocycloalkenyl” refer to a polycyclic heterocycloalkenyl in which two rings shares one atom
- “fused heterocycloalkenyl” refers to a polycyclic heterocycloalkenyl in which two rings shares two adjacent atoms
- “bridged heterocycloalkyl” refers to a heterocycloalkenyl that includes at least two bridgehead atoms and at least one bridging atom.
- “Bridged heterocycloalkenyl” includes “bicyclic bridged heterocycloalkenyl” which includes two bridgehead atoms and “polycyclic bridged heterocycloalkenyl” which includes more than two bridgehead atoms.
- aryl refers to an unsubstituted or substituted mono or polycyclic aromatic ring system containing carbon ring atoms.
- the preferred aryls are mono cyclic or bicyclic aromatic ring systems. Phenyl and naphthyl are preferred aryls.
- heteroaryl represents an aromatic ring system containing carbon (s) and at least one heteroatom.
- Heteroaryl may be monocyclic or polycyclic, substituted or unsubstituted.
- a monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms.
- a polycyclic heteroaryl ring may contain fused, spiro or bridged ring junction, for example, bicyclic heteroaryl is a polycyclic heteroaryl.
- Bicyclic heteroaryl rings may contain from 8 to 12 ring atoms.
- Monocyclic heteroaryl rings may contain from 5 to 8 ring atoms (cabons and heteroatoms) .
- heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, adeninyl, quinolinyl or isoquinolinyl.
- heterocyclyl or “heterocycle” as used herein refers to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple ring system that has at least one heteroatom in the ring (e.g., at least one annular heteroatom selected from oxygen, nitrogen, phosphorus and sulfur) .
- a heterocyclyl group has from 3 to about 20 annular atoms, for example from 3 to 12 annular atoms, for example from 3 to 10 annular atoms, for example from 5 to 10 annular atoms or for example from 5 to 6 annular atoms.
- the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings) having from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring.
- the rings of the multiple condensed ring (e.g. bicyclic heterocyclyl) system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
- heterocyclyl or “heterocyclic ring” or “heterocycle” includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond) .
- a heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro.
- heterocyclyl has 2 to 20 ring carbon atoms (i.e., C 2-20 heterocyclyl) , 2 to 12 ring carbon atoms (i.e., C 2-12 heterocyclyl) , 2 to 10 ring carbon atoms (i.e., C 2-10 heterocyclyl) , 2 to 8 ring carbon atoms (i.e., C 2-8 heterocyclyl) , 3 to 12 ring carbon atoms (i.e., C 3-12 heterocyclyl) , 3 to 8 ring carbon atoms (i.e., C 3-8 heterocyclyl) , or 3 to 6 ring carbon atoms (i.e., C 3-6 heterocyclyl) ; having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms,
- heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl.
- bridged-heterocyclyl refers to a four-to ten-membered cyclic moiety connected at two non-adjacent atoms of the heterocyclyl with one or more (e.g., 1 or 2) four-to ten-membered cyclic moiety having at least one heteroatom where each heteroatom is independently selected from nitrogen, oxygen, and sulfur.
- bridged-heterocyclyl includes bicyclic and tricyclic ring systems.
- spiro-heterocyclyl refers to a ring system in which a three-to ten-membered heterocyclyl has one or more additional ring, wherein the one or more additional ring is three-to ten-membered cycloalkyl or three-to ten-membered heterocyclyl, where a single atom of the one or more additional ring is also an atom of the three-to ten-membered heterocyclyl.
- spiro-heterocyclyl examples include bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro [3.5] nonanyl, 2-oxa-6-azaspiro [3.4] octanyl, and 6-oxa-1-azaspiro [3.3] heptanyl.
- Heterocyclyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems with one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems. Examples include dihydroquinolines (e.g. 3, 4-dihydroquinoline) , dihydroisoquinolines (e.g.
- heterocycles include 3, 8-diazabicyclo [3.2.1] octanyl, 2, 5-diazabicyclo [2.2.1] heptanyl, 3, 6-diazabicyclo [3.1.1] heptanyl, 3-oxa-7, 9-diazabicyclo [3.3.1] nonanyl, and hexahydropyrazino [2, 1-c] [1, 4] oxazinyl, for example.
- the terms “heterocycle” , “heterocyclyl” , and “heterocyclic ring” are used interchangeably.
- any hydrogen atom bonded with C, N, O, or S in the 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 3-12 membered heterocyclyl, 6-10 membered aryl or 5-12 membered heteroaryl can be replaced with the substituent.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
- the present invention includes any possible solvates and polymorphic forms.
- a type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable.
- water, ethanol, propanol, acetone or the like can be used.
- the compounds of this disclosure are capable of forming acid addition salt and/or base addition salt by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- pharmaceutically acceptable salt of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable.
- Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di (substituted alkyl) amines, tri (substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di (substituted alkenyl) amines, tri (substituted alkenyl) amines, mono, di or tri cycloalkyl amines, mono, di or tri arylamines or mixed amines, etc.
- primary, secondary and tertiary amines such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di (substituted alkyl) amines, tri
- Suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri (iso-propyl) amine, tri (n-propyl) amine, ethanolamine, 2-dime thylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
- Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Salts derived from organic acids include salts of acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Since the compounds are intended for pharmaceutical use, they are preferably provided in substantially pure form, for example at least 60%pure, more suitably at least 75%pure, especially at least 98%pure (%are on a weight for weight basis) .
- prodrug refers to a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
- the term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- compositions of the present invention comprise a compound (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
- the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
- the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
- the compounds or a prodrug or a metabolite or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous) .
- the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
- compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion.
- the compound or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
- the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more (such as 1, 2, 3, 4, 5 or 6) necessary ingredients.
- the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
- compositions of this invention may include a pharmaceutically acceptable carrier and the above-mentioned compound or a pharmaceutically acceptable salt thereof.
- the compounds or pharmaceutically acceptable salts thereof can also be included in pharmaceutical compositions in combination with one or more (such as 1, 2, 3, 4, 5 or 6) other therapeutically active compounds.
- a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more (such as 1, 2, 3, 4, 5 or 6) accessory ingredients or adjuvants.
- Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
- a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 0.05 to about 95 percent of the total composition.
- Unit dosage forms will generally contain between from about 0.0lmg to about 2g of the active ingredient, typically 0.01mg, 0.02mg, 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or l000mg.
- compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
- a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
- compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
- the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
- the final injectable form must be sterile and must be effectively fluid for easy syringability.
- the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
- compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound of this invention or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 0.05wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
- compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first mixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
- the pharmaceutical formulations described above may include, as appropriate, one or more (such as 1, 2, 3, 4, 5 or 6) additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- other adjuvants can be included to render the formulation isotonic with the blood of
- dosage levels on the order of from about 0.001mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions or alternatively about 0.05mg to about 7g per patient per day.
- inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) may be effectively treated by the administration of from about 0.001 to 50mg of the compound per kilogram of body weight per day or alternatively about 0.05mg to about 3.5g per patient per day.
- a method of treating a cancer comprising administering to a subject in need thereof a therapeutically-effective amount of a compound of the invention.
- a compound of the invention can, for example, slow the proliferation of cancer cell lines, or kill cancer cells.
- Non-limiting examples of cancer that can be treated by a compound of the invention include: acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, bladder cancer, bone cancers, brain tumors, such as cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma, breast cancer, central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, colon cancer, gallbladder cancer, gastric cancer, head and neck cancer, heart cancer, hepatocellular (liver) cancer, kidney cancer, liver cancer, lung cancers, such as non-small cell and small cell lung cancer, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, pancreatic cancer,
- Step 1 2, 2-trifluoro-1- (7-nitrobenzo [b] thiophen-3-yl) ethan-1-one.
- Step 2 7-nitro-3- (perfluoroethyl) benzo [b] thiophene.
- Step 6 (Z) -3-fluoro-N- (2-iodo-3- (perfluoroethyl) benzo [b] thiophen-7-yl) piperidin-4-amine (racemic) .
- Step 7 (Z) -3-fluoro-N- (2-iodo-3- (perfluoroethyl) benzo [b] thiophen-7-yl) -1-methylpiperidin-4-amine (racemic) .
- Step 8 (4- ( (3- (7- ( ( (Z) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (perfluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (racemic) (1) .
- the reaction mixture was stirred at 50 °C for 3 h.
- the eluate was concentrated under vacuum.
- the resulting crude product was further purified by pre-HPLC with ACN/H 2 O (0.1%ammonium hydroxide) , Flow rate: 70 mL/min; Gradient: 30-70-95%B (2-30-33min) ; 245 nm; RT: 37.76-39.52.
- Step 3 dimethyl (7- (prop-2-yn-1-ylamino) benzofuran-4-yl) phosphine oxide.
- Step 4 (7- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) benzofuran-4-yl) dimethylphosphine oxide (2) .
- the reaction mixture was stirred at 50 °C for 3 h.
- the eluate was concentrated under vacuum.
- the resulting crude product was further purified by pre-HPLC with ACN/H 2 O (0.1%ammonium hydroxide) , Flow rate: 70 mL/min; Gradient: 35-68-71%B (2-30-33min) ; 268 nm; RT: 30.35-32.77.
- Step 1 4-bromo-2- (1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazol-5-yl) aniline.
- Step 2 (4-amino-3- (1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazol-5-yl) phenyl) dimethylphosphine oxide.
- Step 3 (4-amino-3- (1H-pyrazol-5-yl) phenyl) dimethylphosphine oxide.
- Step 4 dimethyl (4- (prop-2-yn-1-ylamino) -3- (1H-pyrazol-5-yl) phenyl) phosphine oxide.
- Step 5 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3- (1H-pyrazol-3-yl) phenyl) dimethylphosphine oxide (3) .
- the reaction mixture was stirred at 50 °C for 3 h.
- the eluate was concentrated under vacuum.
- the resulting crude product was further purified by prep-HPLC with ACN/H 2 O (0.1%ammonium hydroxide) , Flow rate: 70 mL/min; Gradient: 35-67-67%B (2-30-33min) ; 268 nm; RT: 29.55-31.48.
- Step 4 3- (bromomethyl) -7-chlorothieno [2, 3-c] pyridine.
- Step 5 7-chloro-3- (2, 2, 2-trifluoroethyl) thieno [2, 3-c] pyridine.
- Step 6 7-chloro-2-iodo-3- (2, 2, 2-trifluoroethyl) thieno [2, 3-c] pyridine.
- Step 8 (3-methoxy-4- ( (3- (7- ( (1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) thieno [2, 3-c] pyridin-2-yl) prop-2-yn-1-yl) amino) phenyl) dimethylphosphine oxide (4) .
- the reaction mixture was stirred at 50 °C for 3 h.
- the eluate was concentrated under vacuum.
- the resul ting crude product was further purified by prep-HPLC with MeOH/H 2 O (0.1%ammonium hydroxide) , Flow rate: 70 mL/min; Gradient: 35-64-85%B (2-28-46min) ; 260 nm; RT: 35.32-39.48.
- Step 2 tert-butyl (2-methoxy-4-nitrophenyl) (prop-2-yn-1-yl) carbamate.
- Step 3 tert-butyl (4-amino-2-methoxyphenyl) (prop-2-yn-1-yl) carbamate.
- Step 4 ethyl (4- ( (tert-butoxycarbonyl) (prop-2-yn-1-yl) amino) -3-methoxyphenyl) glycinate.
- Step 5 tert-butyl (chlorosulfonyl) carbamate.
- Step 6 ethyl N- (4- ( (tert-butoxycarbonyl) (prop-2-yn-1-yl) amino) -3-methoxyphenyl) -N- (N- (tert-butoxycarbonyl) sulfamoyl) glycinate.
- Step 7 ethyl N- (3-methoxy-4- (prop-2-yn-1-ylamino) phenyl) -N-sulfamoylglycinate.
- Step 8 5- (3-methoxy-4- (prop-2-yn-1-ylamino) phenyl) -1, 2, 5-thiadiazolidin-3-one-1, 1-dioxide.
- Step 9 5- (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen -2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) -1, 2, 5-thiadiazolidin-3-one-1, 1-dioxide (5) .
- the reaction mixture was stirred at 50 °C for 3 h.
- the eluate was concentr ated under vacuum.
- the resulting crude product was further purified by pre-HPLC with ACN/H 2 O (0.1%a mmonium hydroxide) , Flow rate: 70 mL/min; Gradient: 30-70-90%B (2-30-35min) ; 265 nm; RT: 29.50-31.48.
- Step 1 4- ( (2-iodo-3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) amino) tetrahydro-2H-thiopyran-1-oxide.
- the resulting solution was cooled to room temp erature and added to water (50 mL) .
- the resulting solution was extracted with EA (2 x 50 mL) .
- the organic layers were combined and washed with brine (30 mL) , dried over anhydrous Na 2 SO 4 , concentrated under vacuum.
- Step 3 tert-butyl (1-imino-1-oxidohexahydro-1l6-thiopyran-4-yl) (2-iodo-3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) carbamate.
- Step 4 tert-butyl (2- (3- ( (4- (dimethylphosphoryl) -2-methoxyphenyl) amino) prop-1-yn-1-yl) -3- (2, 2, 2-trifluoro ethyl) benzo [b] thiophen-7-yl) (1-imino-1-oxidohexahydro-1l6-thiopyran-4-yl) carbamate.
- Step 5 (4- ( (3- (7- ( (1-imino-1-oxidohexahydro-1l6-thiopyran-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (6) .
- the resulting crude product was further purified by pre-HPLC with ACN/H 2 O (0.05%ammonium hydroxide) , Flow rate: 70 mL/min; Gradient: 35-70-70%B (2-30-60min) ; 266 nm; RT: 19.43-20.51.
- Step 1 (1S, 3S, 4R) -4- ( (2- (3- ( (4- (dimethylphosphoryl) -2-methoxyphenyl) amino) prop-1-yn-1-yl) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) amino) -3-fluoro-1-methylpiperidine-1-oxide (10) and (1R, 3S, 4R) -4- ( (2- (3- ( (4- (dimethylphosphoryl) -2-methoxyphenyl) amino) prop-1-yn-1-yl) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) amino) -3-fluoro-1-methylpiperidine-1-oxide (7) .
- Step 1 (1S, 3S, 4R) -3-fluoro-4- ( (2- (3- ( (2-methoxy-4- ( (R) -S-methylsulfonimidoyl) phenyl) amino) prop-1-yn-1-yl) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) amino) -1-methylpiperidine-1-oxide (8) and (1R, 3S, 4R) -3-fluo ro-4- ( (2- (3- ( (2-methoxy-4- ( (R) -S-methylsulfonimidoyl) phenyl) amino) prop-1-yn-1-yl) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) amino) -1-methylpiperidine-1-oxide (9) .
- the resulting solution was added to saturated Na 2 CO 3 (aq. ) (30 mL) .
- the resulting solution was extracted with DCM (2 x 50 mL) .
- the organic layers were combined and washed with brine (30 mL) , dried over anhydrous Na 2 SO 4 , concentrated under vacuum.
- the resulting crude product was further purified by prep-HPLC with ACN/H 2 O (0.05%ammonium hydroxide) , Flow rate: 70 mL/min; Gradient: 35-55-55%B (2-19-25min) ; 212 nm; RT: 17.80-19.95 and 20.39-22.11.
- Step 4 (4- ( (3- (7- ( (4-fluoro-1-methylpyrrolidin-3-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (13)
- Step 1 tert-butyl 3-fluoro-3- ( (2-iodo-3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) carbamoyl) azetidine-1-carboxylate
- Step 4 N- (2- (3- ( (4- (dimethylphosphoryl) -2-methoxyphenyl) amino) prop-1-yn-1-yl) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) -3-fluoro-1-methylazetidine-3-carboxamide (15)
- thiophen-7-amine 0.530 g, 1.12 mmol
- formaldehyde 0.228 g, 7.59 mmol
- sodium cyanoboronhydride 0.283 g, 6.60 mmol
- MeOH 5 mL
- Step 4 (4- ( (3- (7- ( ( (4-fluoro-1-methylpiperidin-4-yl) methyl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (16)
- Step 8 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (1, 1, 1-trifluoropropan-2-yl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (18) & (4- ( (3- (7- ( ( (3R, 4S) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (1, 1, 1-trifluoropropan-2-yl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (17)
- the reaction mixture was stirred at 50 °C for 2 h. LCMS showed that the reaction was completed.
- Step 1 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) propyl) amino) -3-methoxyphenyl) dimethylphosphine oxide (19)
- Step 5 tert-butyl (S) -5- (dimethylphosphoryl) -2- (hydroxymethyl) indoline-1-carboxylate.
- Step 7 tert-butyl (S) -5- (dimethylphosphoryl) -2-ethynylindoline-1-carboxylate.
- Step 8 tert-butyl (S) -5- (dimethylphosphoryl) -2- ( (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) ethynyl) indoline-1-carboxylate
- reaction was stirred under nitrogen atmosphere at RT for 3 h.
- the reaction mixture was filtered through celite pad and celite pad was washed with ACN (3 x 10 mL) .
- Step 9 (S) -2- ( (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) ethynyl) indolin-5-yl) dimethylphosphine oxide (21)
- the mixture was concentrated to afford the crude product.
- the crude product was purified by preparative HPLC (Mobile Phase A: water (0.05%ammonium hydroxide) , Mobile Phase B: ACN; Flow rate: 70 mL/min; Gradient: 35-68-71%B (2-28-31min) ; 260 nm; 34.960-37.222) to provide the desired product.
- Step 5 tert-butyl (R) -5- (dimethylphosphoryl) -2- (hydroxymethyl) indoline-1-carboxylate.
- Step 7 tert-butyl (R) -5- (dimethylphosphoryl) -2-ethynylindoline-1-carboxylate.
- Step 8 tert-butyl (R) -5- (dimethylphosphoryl) -2- ( (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) ethynyl) indoline-1-carboxylate
- reaction was stirred under nitrogen atmosphere at RT for 3 h.
- the reaction mixture was filtered through celite pad and the celite pad was washed with ACN (3 x 10 mL) .
- Step 9 (R) -2- ( (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) ethynyl) indolin-5-yl) dimethylphosphine oxide (22)
- the mixture was concentrated to afford the crude product.
- the crude product was purified by preparative HPLC (Mobile Phase A: water (0.05%ammonium hydroxide) , Mobile Phase B: ACN; Flow rate: 70 mL/min; Gradient: 35-68-71%B (2-28-31min) ; 260 nm; 34.960-37.222) to provide the desired product.
- Step 4 (4-amino-3-methoxy-2- (methylthio) phenyl) dimethylphosphine oxide.
- Step 5 (3-methoxy-2- (methylthio) -4- (prop-2-yn-1-ylamino) phenyl) dimethylphosphine oxide
- Step 6 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxy-2- (methylthio) phenyl) dimethylphosphine oxide (23)
- the reaction was stirred under nitrogen atmosphere at RT for 16 h.
- the reaction mixture was filtered through celite pad and the celite pad was washed with ACN (3 x 20 mL) .
- the filtrate was then concentrated under reduced pressure to afford the crude product.
- the crude product was purified by preparative HPLC (Mobile Phase A: water (0.1%ammonium hydroxide) , Mobile Phase B: MeOH; Flow rate: 70 mL/min; Gradient: 35-70-95%B (2-30-60min) ; 254 nm; RT: 37.056-39.529) to provide the desired product.
- Step 1 4- ( (3-methoxy-4-nitrophenyl) thio) tetrahydro-2H-pyran
- Step 3 2, 2-trifluoro-N- ( (3-methoxy-4-nitrophenyl) (oxo) (tetrahydro-2H-pyran-4-yl) -l6-sulfaneylidene) acetamide
- Step 5 2, 2-trifluoro-N- ( (3-methoxy-4- (prop-2-yn-1-ylamino) phenyl) (oxo) (tetrahydro-2H-pyran-4-yl) -l6-sulfaneylidene) acetamide
- reaction mixture was filtered through celite pad and celite pad was washed with ACN (3 x 20 mL) .
- LCMS: m/z 405 [M+1] + .
- Step 7 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) (tetrahydro-2H-pyran-4-yl) -l6-sulfanone
- the reaction was stirred under nitrogen atmosphere at RT for 16 h.
- the reaction mixture was filtered through celite pad and the celite pad was washed with ACN (3 x 20 mL) .
- the filtrate was then concentrated under reduced pressure to afford the crude product.
- Step 8. (S) - (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) (tetrahydro-2H-pyran-4-yl) -l6-sulfanone (24) and (R) - (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) (tetrahydro-2H-pyran-4-yl) -l6-sulfanone (25)
- Step 1 isopropyl (3-methoxy-4-nitrophenyl) sulfane
- Step 3 2, 2-trifluoro-N- (isopropyl (3-methoxy-4-nitrophenyl) (oxo) -l6-sulfaneylidene) acetamide
- Step 5 2, 2-trifluoro-N- (isopropyl (3-methoxy-4- (prop-2-yn-1-ylamino) phenyl) (oxo) -l6-sulfaneylidene) acetamide
- the reaction mixture was stirred under nitrogen at 50 °C for 16 h.
- the reaction mixture was filtered through celite pad and the celite pad was washed with ACN (3 x 20 mL) .
- LCMS: m/z 363 [M+1] + .
- Step 7 (R) -imino (isopropyl) (3-methoxy-4- (prop-2-yn-1-ylamino) phenyl) -l6-sulfanone and (S) -imino (isopropyl) (3-methoxy-4- (prop-2-yn-1-ylamino) phenyl) -l6-sulfanone
- Step 8 (S) - (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) (isopropyl) -l6-sulfanone (27)
- the reaction was stirred under nitrogen a tmosphere at RT for 16 h.
- the crude product was purified by preparative HPLC (Mobile Phase A: water (0.05%ammonium hydroxide) , Mobile Phase B: ACN; Flow rate: 70 mL/min; Gradient: 25-55-58%B (2-30-33min) ; 240 nm; 30.59-32.54) to provide the desired product.
- Step 9 (R) - (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) (isopropyl) -l6-sulfanone (26)
- the reaction was stirred under nitrogen at mosphere at RT for 16 h.
- the crude product was purified by preparative HPLC (Mobile Phase A: water (0.05%ammonium hydroxide) , Mobile Phase B: ACN; Flow rate: 70 mL/min; Gradient: 25-55-58%B (2-30-33min) ; 240 nm; 30.59-32.54) to provide the desired product.
- Step 1 (3-methoxy-4- ( (3- (7- ( (1-methylpiperidin-3-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) phenyl) dimethylphosphine oxide.
- Step 2 (R) - (3-methoxy-4- ( (3- (7- ( (1-methylpiperidin-3-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) phenyl) dimethylphosphine oxide (28) and (S) - (3-methoxy-4- ( (3- (7- ( (1-methylpiperidin-3-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) phenyl) dimethylphosphine oxide (29)
- Step6 6- (dimethylphosphoryl) -3- (prop-2-yn-1-ylamino) picolinonitrile.
- Step 1 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- ( (S) -2, 2, 2-trifluoro-1-hydroxyethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (31) , (4- ( (3- (7- ( ( (3R, 4S) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- ( (S) -2, 2, 2-trifluoro-1-hydroxyethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (32) , (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- ( (R)
- the reaction was stirred at 60°C for 1 h under nitrogen.
- the reaction was quenched with water (50 mL) , extracted with EA (2 x 50 mL) .
- the organic layers were combined, washed with brine (2 x 100 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under vacuum.
- the resulting crude product was further purified by pre-HPLC with MeOH/H 2 O (0.1%ammonium hydroxide) , Flow rate: 25 mL/min; Gradient: 50-85-100%B (2-30-60min); 270 nm; RT: 36.800-38.238/40.647-42.205) .
- Step 1 (5- ( (3- (7- ( ( (3R, 4S) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -6-methoxypyridin-2-yl) dimethylphosphine oxide (37) .
- the reaction was stirred at 60°C for 1 h under nitrogen.
- the reaction was quenched with water (50 mL) , extracted with EA (2 x 50 mL) .
- the organic layers were combined, washed with brine (2 x 100 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under vacuum.
- the resulting crude product was further purified by pre-HPLC with ACN/H 2 O (0.05%ammonium hydroxide) , Flow rate: 70 mL/min; Gradient: 30-70-95%B (2-30-60 min) ; 265 nm; RT: 33.005-35.765) .
- the reaction was quenched with saturated aqueous solution of NaHCO 3 (100 mL) , extracted with EA (3 x 100 mL) , The combined organic layers were washed with brine (500 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under vacuum.
- Step3. (4- ( (3- (7- ( ( (3S, 4S) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (38) .
- the reaction was stirred at 60 °C for 2 h under nitrogen.
- the reaction was quenched with water (20 mL) , extracted with EA (30 mL) , The combined organic layers were washed with brine (30 mL) , dried over anhydrous sodium sulfate, filtered and concentrated under vacuum.
- the mixture was purified by preparative HPLC (Mobile Phase A: water (10 mmoL/L ammonium hydroxide) , Mobile Phase B: MeOH; Flow rate: 70 mL/min; Gradient: 50-90-100%B (2-30-40min) ; 270 nm; RT: 26.258-28.090 min) to provide the desired product.
- Step 2 5- (dimethylphosphoryl) -2- (prop-2-yn-1-ylamino) benzonitrile.
- Step 3 5- (dimethylphosphoryl) -N-hydroxy-2- (prop-2-yn-1-ylamino) benzimidamide.
- Step 4 3- (5- (dimethylphosphoryl) -2- (prop-2-yn-1-ylamino) phenyl) -1, 2, 4-oxadiazol-5 (2H) -one.
- Step 5 3- (5- (dimethylphosphoryl) -2- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) phenyl) -1, 2, 4-oxadiazol-5 (2H) -one (39) .
- the reaction mixture was stirred at room temperature for 1 h. LCMS showed that the reaction was completed.
- the mixture was purified by prep-HPLC (Mobile Phase A: water (10 mmoL/L ammonium hydroxide) , Mobile Phase B: ACN; Flow rate: 40 mL/min; Gradient: 35-69-69%B (2-30-60min) ; 266 nm; RT: 6.45 –7.91 min) .
- Step 3 3-methoxy-4- (prop-2-yn-1-ylamino) benzonitrile.
- Step 4 N-hydroxy-3-methoxy-4- (prop-2-yn-1-ylamino) benzimidamide.
- Step 5 3- (3-methoxy-4- (prop-2-yn-1-ylamino) phenyl) -1, 2, 4-oxadiazol-5 (2H) -one.
- Step 3 (3-methoxy-2-methyl-4- (prop-2-yn-1-ylamino) phenyl) dimethylphosphine oxide.
- Step 4 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxy-2-methylphenyl) dimethylphosphine oxide (41) .
- Step 1 4-bromo-2-methoxy-3- (trifluoromethyl) aniline.
- Step 2 (4-amino-3-methoxy-2- (trifluoromethyl) phenyl) dimethylphosphine oxide.
- Step 3 (3-methoxy-4- (prop-2-yn-1-ylamino) -2- (trifluoromethyl) phenyl) dimethylphosphine oxide.
- Step 4 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxy-2- (trifluoromethyl) phenyl) dimethylphosphine oxide (42) .
- the reaction mixture was stirred at room temperature for 1 h. LCMS showed that the reaction was completed.
- the mixture was purified by prep-HPLC (Mobile Phase A: water (10 mmoL/L ammonium hydroxide) , Mobile Phase B: ACN; Flow rate: 40 mL/min; Gradient: 25-75-75%B (2-30-60min) ; 266 nm; RT: 52.053 –53.667 min) .
- Step 5 (4-amino-2-ethoxy-3-methoxyphenyl) dimethylphosphine oxide.
- Step 6 (2-ethoxy-3-methoxy-4- (prop-2-yn-1-ylamino) phenyl) dimethylphosphine oxide.
- Step 7 (2-ethoxy-4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) dimethylphosphine oxide (43) .
- the reaction mixture was stirred at room temperature for 1 h. LCMS showed that the reaction was completed.
- the mixture was purified by prep-HPLC (Mobile Phase A: water (10 mmoL/L ammonium hydroxide) , Mobile Phase B: ACN; Flow rate: 40 mL/min; Gradient: 25-75-75%B (2-30-60min) ; 266 nm; RT: 52.053 –53.667 min) .
- Step 2 imino (6-methoxy-5-nitropyridin-2-yl) (methyl) -l6-sulfanone.
- Step 4.2 2, 2-trifluoro-N- ( (6-methoxy-5- (prop-2-yn-1-ylamino) pyridin-2-yl) (methyl) (oxo) -l6-sulfaneylidene) acetamide
- Step 6 (5- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -6-methoxypyridin-2-yl) (imino) (methyl) -l6-sulfanone
- Step 7 (S) - (5- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -6-methoxypyridin-2-yl) (imino) (methyl) -l6-sulfanone (45) and (R) - (5- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -6-methoxypyridin-2-yl) (imino) (methyl) -l6-sulfanone (44)
- Step 1 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3- (methoxy-d3) phenyl) dimethylphosphine sulfide (47) .
- LCMS showed that the reaction was completed.
- the mixture was purified by prep-HPLC (Mobile Phase A: water (10 mmoL/L ammonium hydroxide) , Mobile Phase B: ACN; Flow rate: 40 mL/min; Gradient: 25-75-75%B (2-30-60min) ; 266 nm; RT: 52.053 –53.667 min) .
- Step 1 N- (2-iodo-3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) quinuclidin-3-amine.
- Step 2 (3-methoxy-4- ( (3- (7- (quinuclidin-3-ylamino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) phenyl) dimethylphosphine oxide.
- N- (2-iodo-3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-7-yl) quinuclidin-3-amine (0.412 g, 0.88 mmol) , CuI (0.091 g, 0.51 mmol) , Pd (PPh 3 ) 2 Cl 2 (0.198 g, 0.272 mmol) , DIEA (0.318 g, 2.46 mmol) and DMF (5 mL) .
- Step 3 (S) - (3-methoxy-4- ( (3- (7- (quinuclidin-3-ylamino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) phenyl) dimethylphosphine oxide (48) and (R) - (3-methoxy-4- ( (3- (7- (quinuclidin-3-ylamino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) phenyl) dimethylphosphine oxide (46)
- Step 2 3- ( (3-methoxy-4-nitrophenyl) thio) oxetane.
- Step 3 imino (3-methoxy-4-nitrophenyl) (oxetan-3-yl) -l6-sulfanone.
- Step 4 tert-butyl ( (3-methoxy-4-nitrophenyl) (oxetan-3-yl) (oxo) -l6-sulfaneylidene) carbamate.
- Step 7 tert-butyl ( (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (oxetan-3-yl) (oxo) -l6-sulfaneylidene) carbamate
- Step 8 (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2 -yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) (oxetan-3-yl) -l6-sulfanone
- Step 9 (S) - (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) (oxetan-3-yl) -l6-sulfanone (50) and (R) - (4- ( (3- (7-( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) (oxetan-3-yl) -l6-sulfanone (49)
- Step 1 (difluoromethyl) (3-methoxy-4-nitrophenyl) sulfane.
- Step 3 (4-amino-3-methoxyphenyl) (difluoromethyl) (imino) -l6-sulfanone.
- Step 1 cyclopropyl (3-methoxy-4-nitrophenyl) sulfane.
- Step 2 cyclopropyl (imino) (3-methoxy-4-nitrophenyl) -l6-sulfanone.
- Step 3 N- (cyclopropyl (3-methoxy-4-nitrophenyl) (oxo) -l6-sulfaneylidene) -2, 2, 2-trifluoroacetamide.
- Step 7 cyclopropyl (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) -l6-sulfanone
- Step 8 (S) -cyclopropyl (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) -l6-sulfanone (54) and (R) -cyclopropyl (4- ( (3- (7- ( ( (3S, 4R) -3-fluoro-1-methylpiperidin-4-yl) amino) -3- (2, 2, 2-trifluoroethyl) benzo [b] thiophen-2-yl) prop-2-yn-1-yl) amino) -3-methoxyphenyl) (imino) -l6-sulfanone (53)
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (I) qui peuvent se lier à p53 mutant et restaurer la capacité du mutant de p53 à se lier à l'ADN et à activer des effecteurs en aval impliqués dans la suppression de tumeurs. L'invention concerne également des compositions pharmaceutiques comprenant les composés, des procédés de préparation des composés et des procédés d'utilisation des composés pour prévenir ou traiter une maladie ou un état associé à des mutants de p53.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022137535 | 2022-12-08 | ||
CNPCT/CN2022/137535 | 2022-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024120471A1 true WO2024120471A1 (fr) | 2024-06-13 |
Family
ID=91378604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/136981 WO2024120471A1 (fr) | 2022-12-08 | 2023-12-07 | Composés ciblant un mutant de p53 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024120471A1 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109069481A (zh) * | 2016-02-19 | 2018-12-21 | 皮姆维制药公司 | 用于恢复突变p53功能的方法和化合物 |
WO2021262484A1 (fr) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Polythérapie pour le traitement du cancer |
WO2021262483A1 (fr) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Méthodes et composés pour la restauration de la fonction du p53 mutant |
WO2021262541A1 (fr) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Outil de diagnostic compagnon pour composés de réactivation de p53 mutantes |
CN115003299A (zh) * | 2019-09-23 | 2022-09-02 | 皮姆维制药公司 | 用于恢复突变体p53功能的方法和化合物 |
WO2023016434A1 (fr) * | 2021-08-10 | 2023-02-16 | Jacobio Pharmaceuticals Co., Ltd. | Composés ciblant un mutant de p53 |
CN115724784A (zh) * | 2021-08-27 | 2023-03-03 | 杭州紫晶医药科技有限公司 | 作为p53调节剂和/或hdac抑制剂的化合物 |
-
2023
- 2023-12-07 WO PCT/CN2023/136981 patent/WO2024120471A1/fr unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109069481A (zh) * | 2016-02-19 | 2018-12-21 | 皮姆维制药公司 | 用于恢复突变p53功能的方法和化合物 |
CN115003299A (zh) * | 2019-09-23 | 2022-09-02 | 皮姆维制药公司 | 用于恢复突变体p53功能的方法和化合物 |
WO2021262484A1 (fr) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Polythérapie pour le traitement du cancer |
WO2021262483A1 (fr) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Méthodes et composés pour la restauration de la fonction du p53 mutant |
WO2021262541A1 (fr) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Outil de diagnostic compagnon pour composés de réactivation de p53 mutantes |
WO2023016434A1 (fr) * | 2021-08-10 | 2023-02-16 | Jacobio Pharmaceuticals Co., Ltd. | Composés ciblant un mutant de p53 |
CN115724784A (zh) * | 2021-08-27 | 2023-03-03 | 杭州紫晶医药科技有限公司 | 作为p53调节剂和/或hdac抑制剂的化合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112638917B (zh) | 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 | |
CN113286794B (zh) | Kras突变蛋白抑制剂 | |
WO2019192506A1 (fr) | Immunomodulateurs, compositions et procédés associés | |
US10022374B2 (en) | Certain protein kinase inhibitors | |
WO2019037678A1 (fr) | Dérivé de pyrazolo[3,4-d]pyrimidin-3-one, composition pharmaceutique et utilisation associée | |
WO2019193540A1 (fr) | Dérivés hétéroaryles de formule (i) utilisés en tant qu'inhibiteurs d'atf4 | |
WO2020012339A1 (fr) | Composés chimiques | |
WO2015127872A1 (fr) | Dérivés de 1,5-diamine phénylène 2,4-disubstitués et leurs applications, compositions pharmaceutiques et compositions pharmaceutiquement acceptables préparées à partir de ces dérivés | |
WO2012080284A2 (fr) | Composés hétérocycliques azotés 6,6-condensés substitués et leurs utilisations | |
WO2020011243A1 (fr) | Immunomodulateurs, compositions et procédés associés | |
WO2016011979A1 (fr) | Dérivé 7h-pyrrolo[2,3-d]pyrimidine 2,4-disubstituté, procédé de préparation et utilisation médicinale de ce dernier | |
WO2020031107A1 (fr) | Composés chimiques | |
JP2018052878A (ja) | ピリジン化合物 | |
WO2023016434A1 (fr) | Composés ciblant un mutant de p53 | |
CN111518100A (zh) | 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用 | |
CN110655520A (zh) | 嘧啶并环化合物及其制备方法和应用 | |
CA3066328A1 (fr) | Composes chimiques utilises comme inhibiteurs de la voie atf4 | |
CN110818641B (zh) | 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用 | |
CA3117319A1 (fr) | Heterocycles bicycliques fusionnes en tant qu'agents therapeutiques | |
WO2020057669A1 (fr) | Composé hétérocyclique aromatique ayant une activité inhibitrice de kinase | |
WO2024120471A1 (fr) | Composés ciblant un mutant de p53 | |
WO2022262691A1 (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de sos1 | |
WO2022171088A1 (fr) | Dérivé de pyrazolo[3,4-d]pyrimidin-3-one | |
WO2022032484A1 (fr) | Composé de pyridazine-3-formamide, son procédé de préparation et son utilisation médicale | |
WO2024041503A1 (fr) | Composés ciblant le mutant y220c de p53 |